News

Enlarge image

PoliticsEU

New president fires against EU

25.06.2013 - Sanofi’s CEO Christopher Viehbacher has been elected head of Europe’s pharma lobby organisation EFPIA. He started off with threatening EU politicians.

Christopher A. Viehbacher, Chief Executive Officer of Sanofi, was elected President of EFPIA, the European Federation of Pharmaceutical Industries and Associations, for a 2-year term. Viehbacher, holding both German and Canadian nationalities, took the chance after the election on June 24 to take up a stance on EU politics. The quarrel is about the European Medicine Agency’s (EMA) strategy to make drug development more transparent by disclosing data from clinical studies. The EMA hopes that the released data on already approved drugs could spur research in general. The industry, however, believes competitors from the biologics field may gain valuable information and thus feels bullied. Speaking of his very own Sanofi, Viehbacher argues in a Reuters release: „If I was to say where would I put the next euro of investment, I would say either the next euro of investment would go to the United States or to emerging markets.“ The data in question also includes information that may help competitors in the field, Viehbacher fears that other companies like GSK or Roche got less exercised on the issue. They plan to open the corresponding raw data files for qualified researchers.

Beyond that discussion, Viehbacher also identified other construction sites, The EFPIA head urged: „Given the chronic deficits of healthcare systems, we must work differently, build collaborative policies and combine our strengths at both national and European levels. As we want Healthcare to be a growth engine for Europe, our industry must focus on three priorities: patient access, science & innovation and competitiveness.” Viehbacher follows Andrew Witty from UK’s GlaxoSmithKline. Joining him at the head of the EFPIA board will be two newly elected Vice Presidents, Roch Doliveux, Chief Executive Officer of UCB, and Joseph Jimenez, Chief Executive Officer of Novartis.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/new-president-fires-against-eu.html

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ZEALAND PHARMA (DK)130.50 DKK11.06%

FLOP

  • BIOFRONTERA (D)2.84 EUR-4.70%
  • CHRONTECH PHARMA (S)0.34 SEK-2.86%
  • PHOTOCURE (N)41.50 NOK-2.35%

TOP

  • GALAPAGOS (B)52.23 EUR29.6%
  • NICOX (F)10.89 EUR26.8%
  • RENEURON (UK)3.70 GBP26.7%

FLOP

  • BIONOR PHARMA (N)0.70 NOK-23.1%
  • BIOCARTIS GROUP NV (B)8.32 EUR-23.0%
  • MOBERG PHARMA (S)38.70 SEK-23.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)29.50 SEK1992.2%
  • NICOX (F)10.89 EUR482.4%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.95 SEK-87.0%
  • BB BIOTECH (D)44.62 EUR-84.3%
  • BIOTEST (D)17.10 EUR-77.5%

No liability assumed, Date: 25.05.2016